Sirolimus-eluting coronary stent - Lepu Medical Technology (Beijing)

Drug Profile

Sirolimus-eluting coronary stent - Lepu Medical Technology (Beijing)

Alternative Names: NeoVas BCS - Lepu Medical Technology; NeoVas bioresorbable coronary scaffold - Lepu Medical Technology

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lepu Medical Technology (Beijing)
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunosuppressants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Coronary artery disease

Most Recent Events

  • 26 Aug 2017 Efficacy data from a clinical trial in Coronary artery disease presented at the the ESC Congress 2017: Annual Congress of the European Society of Cardiology (ESC-2017)
  • 26 Aug 2017 Lepu Medical Technology (Beijing) completes the clinical trial in Coronary artery disease in China
  • 31 Mar 2017 Phase-II development is ongoing in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top